Convert Pharmaceuticals is a pioneering platform company specializing in the development of prodrugs that remain inert until they reach the tumor site. These innovative drugs then transform into powerful anti-cancer agents within the tumor microenvironment. Leveraging proprietary insights into tumor biology and specific biomarkers, Convert Pharmaceuticals meticulously designs prodrugs to specifically target tumor hypoxia, a major contributor to cancer treatment resistance.
Tumor hypoxia is a common characteristic found in approximately 50% of solid tumors. Through our cutting-edge development of two key biomarkers, we have discovered that certain cancer types are particularly responsive to our therapies. These include pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, and head and neck squamous cell carcinoma, positioning our treatments at the forefront of combating these challenging diseases.
In this news, we would like to break down how hypoxia fuels cancer, why past attempts to target it failed, and how we’re working to turn hypoxia into a weapon against itself. Part 1: Tumor Hypoxia – The “Stealth Mode” of Cancer Tumor hypoxia refers......
Convert Pharmaceuticals has achieved a major milestone by securing the maximum €2.5 million non-dilutive grant from the prestigious European Innovation Council (EIC) Accelerator program. This competitive funding, awarded by a panel of experts, highlights the company’s innovative potential and supports its ongoing Series A investment......
Yale School of Medicine’s Latest Validation on Advancing Cancer Treatment Through Hypoxia-Targeted Therapies Supports Convert Pharmaceuticals’ Strategy Their recent findings supported by research professionals at AstraZeneca, Johnson & Johnson, and others published in the Journal of Experimental Medicine, provide critical insights into the role of......